National Institute Clinical Excellence (NICE) 2008. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention on cardiovascular disease. Nice Guideline (CG67). Update in guideline (CG181).
. Main C, Kniht B, Moxham T, Gabriel Sánchez R, Sánchez Gómez L, Roqué i Figuls M et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2013;4:CD002229
. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;7:CD004143.
Antithrombotic Trialist Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1949-60
Raju N, Sobieraj-Teague M, Hirsh J et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621-9.
Seshasai SRK, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes. Meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:209-16.
US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009;150:396-404.
Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-1701